240 related articles for article (PubMed ID: 38318172)
1. Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis.
Zhang C; Wei F; Ma W; Zhang J
Front Immunol; 2024; 15():1255825. PubMed ID: 38318172
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
Front Immunol; 2022; 13():908173. PubMed ID: 35880172
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Guo X; Li W; Hu J; Zhu EC; Su Q
Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Tian Y; Gao A; Wen Q; Wang S; Zhang S; Yang X; Su G; Sun Y
Front Immunol; 2020; 11():595655. PubMed ID: 33391266
[TBL] [Abstract][Full Text] [Related]
8. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
9. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
10. Toxicities associated with immune checkpoint inhibitors: a systematic study.
Kong X; Chen L; Su Z; Sullivan RJ; Blum SM; Qi Z; Liu Y; Huo Y; Fang Y; Zhang L; Gao J; Wang J
Int J Surg; 2023 Jun; 109(6):1753-1768. PubMed ID: 37132038
[TBL] [Abstract][Full Text] [Related]
11. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
Xu M; Nie Y; Yang Y; Lu YT; Su Q
Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis.
Huang S; Zheng G; Yang K
World J Surg Oncol; 2023 Nov; 21(1):349. PubMed ID: 37926852
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
14. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
15. Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis.
Tian Y; Huang A; Tian M; Wang K; Dang Q; Zhang C; Liu H; Zhao J; Yang X; Zhang C; Guo L; Chen F
Medicine (Baltimore); 2022 Sep; 101(36):e30151. PubMed ID: 36086680
[TBL] [Abstract][Full Text] [Related]
16. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
Miyashita H; Mikami T; Satoi S; Cruz C; Galsky MD
J Immunother; 2020; 43(9):291-298. PubMed ID: 32960847
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.
Li H; Xu J; Bai Y; Zhang S; Cheng M; Jin J
Invest New Drugs; 2021 Jun; 39(3):860-870. PubMed ID: 33409896
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
[TBL] [Abstract][Full Text] [Related]
20. Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs).
Long YX; Sun Y; Liu RZ; Zhang MY; Zhao J; Wang YQ; Zhou YW; Cheng K; Chen Y; Zhu CR; Liu JY
Curr Oncol; 2022 Jan; 29(1):267-282. PubMed ID: 35049699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
